@article {VALAN871, author = {CHRISTINE D. VALAN and JENS E. SLAGSVOLD and TARJE ONS{\O}IEN HALVORSEN and MARTIN HERJE and ROY M. BREMNES and PAAL F. BRUNSVIG and ODD T. BRUSTUGUN and {\O}YSTEIN FL{\O}TTEN and NINA LEVIN and STEIN H. SUNDSTR{\O}M and BJ{\O}RN H. GR{\O}NBERG}, title = {Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement}, volume = {38}, number = {2}, pages = {871--876}, year = {2018}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and Methods: Patients with a baseline CT scan available were analysed. Patients received four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Results: Median overall survival (OS) was 23.3 months in the whole cohort. N3-patients (n=37) had shorter survival than those with N0-2 (16.7 vs. 33.0 months; p\<0.001). There were no significant OS-differences between the N3 subcategories, but patients with metastases to two or more N3 regions had shorter survival than other N3 patients (13.4 vs. 19.9 months; p=0.011). Conclusion: There were no survival differences between the N3 subcategories, suggesting that all N3 disease should be considered as LD.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/2/871}, eprint = {https://ar.iiarjournals.org/content/38/2/871.full.pdf}, journal = {Anticancer Research} }